cilgavimab
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Evusheld | — | 2025-09-12 | europa.eu ↗ |
| Approved | EU (EMA) | Evusheld | — | 2022-03-25 | europa.eu ↗ |
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05281601 | Mar 2022 → Apr 2024 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05437289 | Oct → Nov 2021 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04896541 | Mar 2021 → Jun 2022 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04507256 | Aug 2020 → Oct 2021 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05465876 | Oct 2023 → Oct 2024 | B-cell chronic lymphocytic leukemia, COVID-19 | Sunnybrook Health Sciences Centre | Withdrawn | No outcome recorded |
| Phase 2 | NCT05375760 | Jun 2022 → Oct 2023 | COVID-19 | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT05184062 | Dec 2021 → Aug 2022 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05648110 | Dec 2022 → Mar 2024 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
| Phase 2/3 | NCT04518410 | Aug 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT05438498 | Jun 2022 → Apr 2023 | COVID-19 | MediMergent, LLC | Terminated | No outcome recorded |
| Phase 3 | NCT05321394 | Mar 2022 → Oct 2023 | COVID-19 | Azienda Ospedaliera Universitaria Integrata Verona | Completed | No outcome recorded |
| Phase 3 | NCT05780437 | Feb 2021 → Jan 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04723394 | Jan → Aug 2021 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04501978 | Aug 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04315948 | Mar 2020 → Jul 2022 | COVID-19 | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05982704 | Aug → Sep 2022 | COVID-19 | City Clinical Hospital No.52 of Moscow Healthcare Department | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05166421 Comparator | Nov 2021 → Jul 2023 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05041907 Comparator | Sep 2021 → Jan 2027 expected | COVID-19 | University of Oxford | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05271929 Background | Apr 2022 → Jan 2024 | COVID-19 | German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cilgavimab | “Safety, pharmacokinetics, and impact of race of pharmacokinetics on monoclonal antibodies tixagevimab and cilgavimab (AZD7442) were assessed in Chinese adult participants in a...” PMID 40910575 ↗ Sep 202512“BACKGROUND: AZD7442 is a combination of extended half-life, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific neutralizing monoclonal antibodies...” PMID 36683419 ↗ May 2023 “AZD7442 (Evusheld) is a combination of two human anti-severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs), tixagevimab (AZD8895) and...” PMID 35797235 ↗ Jul 2022 “AZD7442, a combination of extended half-life monoclonal antibodies tixagevimab and cilgavimab, was shown to neutralize previously circulating SARS-CoV-2 variants.” PMID 40799036 ↗ Aug 2025 “EVUSHELD is a combination of 2 monoclonal antibodies (mAbs), Tixagevimab and Cilgavimab.” NCT05465876 ↗ “Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0” NCT05041907 ↗ “AZD1061 \[cilgavimab, a component of AZD7442 (EVUSHELD)\]” NCT05648110 ↗ “one each of 300 mg tixagevimab and 300 mg cilgavimab” PMID 35688164 ↗ Jun 2022 “Tixagevimab / Cilgavimab (Evusheld)” NCT05271929 ↗ |
| Known as | 2130 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650258 ↗ |
| Known as | AZD1061 | “AZD8895 and AZD1061, known collectively as AZD7442, are two fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibodies (mAb) that target two distinct...” NCT05780437 ↗7“AZD7442 will be supplied as separate vials of AZD8895 and AZD1061 containing 150 mg colorless to slightly yellow, clear to opalescent solutions for injection.” NCT04315948 ↗ “IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order.” NCT05281601 ↗ “AZD7442, a combination of 2 of these mAbs (AZD8895 and AZD1061), is being evaluated for administration to treat or prevent COVID-19.” NCT04896541 ↗ “600 mg AZD5156 consisting of 300 mg AZD1061 at 100 mg/mL and 300 mg AZD3152 at 150 mg/mL” NCT05648110 ↗ “cilgavimab [investigational name, AZD1061]” NCT05375760 ↗ |
| Known as | COV2-2130 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650258 ↗ |
| Modality | Monoclonal antibody | “BACKGROUND: AZD7442 is a combination of extended half-life, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific neutralizing monoclonal antibodies...” PMID 36683419 ↗ May 2023 |
| Route | Intravenous | “Participants randomized to the AZD7442 group will receive a total dose of 600 mg AZD7442 via a co-administered (300 mg AZD8895 and 300 mg AZD1061) single IV infusion on Day 1.” NCT04315948 ↗ |